SGO Winter Meeting

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.